Singapore markets closed

BSGM May 2024 2.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
At close: 02:48PM EDT
Full screen
Previous close0.1500
Open0.2000
Bid0.1500
Ask0.2500
Strike2.50
Expiry date2024-05-17
Day's range0.1000 - 0.2000
Contract rangeN/A
Volume51
Open interest279
  • GlobeNewswire

    BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent

    Westport, CT, May 03, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced new appointments to its now fully constituted board of directors (the “Board”), which is comprised of a total of five (5) directors, three (3) of whom are classified as independent directors. The final compositions of the committees to the Board wi

  • GlobeNewswire

    BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

    Mr. Amato will also serve on the Company’s Board of DirectorsWestport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer (“CEO”), effective immediately. Additionally, Mr. Amato will serve on the Company’s Board of Directors, w

  • GlobeNewswire

    BioSig Engages Consulting Firm for Business Model Strategies

    BAIPC will work to deploy a series of solutions to transform BioSig’s future courseWestport, CT, April 04, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that it appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies. BAIPC will work to deploy a series of solut